June 6 (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc is in talks to sell its Bausch & Lomb unit’s surgical products business to Germany’s Carl Zeiss Meditec AG, Bloomberg reported.
Valeant's eye-surgery assets may be valued at about $2 billion in a sale, Bloomberg reported, citing people familiar with the matter. (bloom.bg/2sckufc)
Valeant and Carl Zeiss were not immediately available for comment. (Reporting by Ahmed Farhatha in Bengaluru; Editing by Maju Samuel)